Logotype for Beam Therapeutics Inc

Beam Therapeutics (BEAM) Study result summary

Event summary combining transcript, slides, and related documents.

Logotype for Beam Therapeutics Inc

Study result summary

27 Oct, 2026

BEAM-301 study design

  • Open-label Phase I/II single-dose IV study in GSD1a patients with R83C; six treated (three each at 20 mg and 40 mg); median follow-up 7.6 months (range 1.9–16.6) at the Aug. 17, 2026 cutoff.

  • The 60 mg cohort is enrolling 3–6 patients to assess safety, fasting tolerance and changes in starch supplementation.

BEAM-301 clinical findings

  • Median time to fasting hypoglycemia rose from 2.9 to 4.3 hours at Day 36 in the 20 mg cohort, and from 2.5 to 15.0 hours in the 40 mg cohort.

  • At 40 mg, 2 of 3 patients reached the 15-hour maximum controlled fast, with glucose generally remaining in the euglycemic range.

  • Two of 3 patients at 40 mg stopped starch supplementation at their latest assessments; CGM showed more time euglycemic and less hyperglycemic despite reduced starch, with no overall increase in hypoglycemia time.

  • The 40 mg nonresponder had BMI above 50; lower liver exposure from fixed dosing and compound heterozygosity were proposed as possible factors.

  • Findings were described as clinical proof of concept for single-dose correction intended to restore endogenous glucose production.

Safety and dose evaluation

  • Safety was described as acceptable and consistent with IV LNP risks; no dose-limiting toxicities, treatment-related discontinuations or Grade 4/5 treatment-emergent adverse events were reported.

  • Four of six patients had serious treatment-related adverse events, including three Grade 3 infusion reactions; diarrhea and rhabdomyolysis also resolved.

  • Infusion-related reactions and transient transaminase elevations were most frequent; liver enzyme elevations resolved without treatment, with all but one Grade 2 AST elevation classified as Grade 1.

  • Steroid premedication and infusion regimens were modified after Grade 3 infusion reactions; investigators supported escalation to 60 mg.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more

Latest events from Beam Therapeutics